Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss
Abstract
The FDA has approved orforglipron (Foundayo – Lilly), an oral small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and at least one weight-related comorbidity. Orforglipron is the second oral GLP-1 receptor agonist to be approved in the US for this indication; an oral formulation of the peptide semaglutide (Wegovy) was approved in 2025.
Fields of Study & Subjects
Diabetes Treatment and Management
Pharmacology and Obesity Treatment
Bariatric Surgery and Outcomes
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Publisher
- The Medical Letter, Inc.
- Volume
- 68
- Issue
- 1755
- Pages
- 81–83
- Publication date
- 25 May 2026
- Language
- EN